all 1 comments

[–]infocom6502 1 insightful - 1 fun1 insightful - 0 fun2 insightful - 1 fun -  (0 children)

This could be why FDA is cancelling a 2020 promise of meeting intended for discussion of data and public transparency.

Aug 20

Last year the FDA said it was “committed to use an advisory committee composed of independent experts to ensure deliberations about authorisation or licensure are transparent for the public.”1 But in a statement, the FDA told The BMJ that it did not believe a meeting was necessary ahead of the expected granting of full approval. [....]

Kim Witczak, a drug safety advocate who serves as a consumer representative on the FDA’s Psychopharmacologic Drugs Advisory Committee,4 said the decision removed an important mechanism for scrutinising the data.

“These public meetings are imperative in building trust and confidence especially when the vaccines came to market at lightning speed under emergency use authorisation,” she said. “The public deserves a transparent process, especially as the call for boosters and mandates are rapidly increasing. These meetings offer a platform where questions can be raised, problems tackled, and data scrutinised in advance of an approval.”

There is more discussion of this around or after minute 36 of a long TLAV podcast.